Retatrutide Pen 30 mg Viogen

Remedium Retatrutide 30mg Pen is a triple-agonist GLP-1 research compound designed for advanced metabolic and appetite-regulation studies, supplied in a precision prefilled pen for controlled dosing.

Retatrutide Pen is a next-generation GLP-1/GIP/GCGR receptor agonist formulated for advanced metabolic and weight-management research. Designed in a convenient prefilled pen format, this product delivers precise dosing with enhanced user control and consistency. Retatrutide is recognised for its multi-pathway mechanism, supporting appetite regulation, metabolic efficiency, and fat utilisation. The Remedium pen format offers accuracy, reduced preparation time, and improved handling compared to traditional vial systems. – Remedium Retatrutide 30mg Pen

Key Features

• 30mg Retatrutide per prefilled pen
• Triple-agonist metabolic research compound
• Precision dosing delivery system
• Manufactured under controlled laboratory conditions
• Designed for advanced research and investigational use

How It Works

Retatrutide targets GLP-1, GIP, and glucagon receptors, working synergistically to regulate appetite signals, enhance metabolic output, and influence energy balance. This triple-pathway action makes it distinct from single or dual agonist compounds.

How to Use

• Administer according to structured research protocols
• Pen format allows controlled and measured dosing
• Not intended for human therapeutic use